KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Leases: 2019-2025

Historic Current Leases for Xenon Pharmaceuticals (XENE) over the last 6 years, with Sep 2025 value amounting to $1.5 million.

  • Xenon Pharmaceuticals' Current Leases rose 7.79% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 7.79%. This contributed to the annual value of $1.4 million for FY2024, which is 5.39% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Current Leases stood at $1.5 million for Q3 2025, which was up 2.47% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Current Leases registered a high of $1.5 million during Q3 2025, and its lowest value of $270,000 during Q1 2021.
  • In the last 3 years, Xenon Pharmaceuticals' Current Leases had a median value of $1.4 million in 2024 and averaged $1.3 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Current Leases fell by 19.34% in 2022 and then surged by 166.19% in 2023.
  • Xenon Pharmaceuticals' Current Leases (Quarterly) stood at $605,000 in 2021, then declined by 19.34% to $488,000 in 2022, then soared by 166.19% to $1.3 million in 2023, then increased by 5.39% to $1.4 million in 2024, then increased by 7.79% to $1.5 million in 2025.
  • Its Current Leases was $1.5 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.4 million in Q1 2025.